Compare IDE & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDE | GNLX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.6M | 202.4M |
| IPO Year | N/A | 2023 |
| Metric | IDE | GNLX |
|---|---|---|
| Price | $12.28 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 33.5K | ★ 111.5K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.61 | $1.99 |
| 52 Week High | $10.46 | $8.54 |
| Indicator | IDE | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 41.11 |
| Support Level | $12.05 | $4.21 |
| Resistance Level | $12.10 | $4.46 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 84.09 | 46.90 |
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.